COMPANY
Airway Therapeutics
Airway Therapeutics is listed on ClinicalTrials.gov as the lead sponsor of 3 studies; the most recently updated is “Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)” (Phase 2, Phase 3, recruiting), in Bronchopulmonary Dysplasia. Airway Therapeutics has received NIH funding, most recently in fiscal 2026 for the project “A Randomized,Phase 2b/3 Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing BPD in High-Risk Preterm Neonates Compared to Standard of Care”. From public records Source · Oct 12, 2026
Funding and NIH signals
- SEC Form D raise Raised $43.5M (Form D filed Sep 9, 2026). SEC Form D 0000914062-26-000054 (Sep 9, 2026)
Evidence (1 event)
- Sep 9, 2026 · SEC Form D 0000914062-26-000054
Name of Issuer: Airway Therapeutics, Inc.; CIK: 1733867; Address: Marietta, GA; Submission type: D; Filing date: 2026-09-09; Industry Group: Biotechnology; Date of First Sale: 2026-08-10; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 50584517; Total Amount Sold: 43496282; Federal exemptions: 06b
- Sep 9, 2026 · SEC Form D 0000914062-26-000054
- NIH award NIH awarded $1.91M (SBIR Phase II 1R44HL186892-01, new, notice Sep 10, 2026). NIH RePORTER 1R44HL186892-01 (Sep 10, 2026)
Evidence (1 event)
- Sep 10, 2026 · NIH RePORTER 1R44HL186892-01
Organization: AIRWAY THERAPEUTICS, INC.; City/State: Atlanta, GA; Project number: 1R44HL186892-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 1906253; Administering IC: National Heart Lung and Blood Institute; Project title: A Randomized,Phase 2b/3 Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing BPD in High-Risk Preterm Neonates Compared to Standard of Care.; Organization type: Domestic For-Profits
- Sep 10, 2026 · NIH RePORTER 1R44HL186892-01
Raises and deals from press releases
- Raise Series E · $24M · announced Aug 25, 2026 Company release ↗
Source quote
- Aug 25, 2026 · Company release ↗
“The E-round consists of $26 million previously raised through a SAFE financing and $24 million through the Company’s Series E-2 round.”
- Aug 25, 2026 · Company release ↗
Timeline
- Raise Series E · $24M source ↗
- Trial start Phase 2/Phase 3: Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) source ↗
- Trial start Phase 1: A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD) source ↗
- Trial start Phase 1: A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia source ↗
Upcoming milestones
- Mar 31, 2028 (ESTIMATED) · Phase 2/Phase 3 · Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) · NCT06897839
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06897839 | Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) | Phase 2/Phase 3 | Recruiting | Feb 3, 2025 | Mar 31, 2028 (estimated) |
| NCT04662151 | A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD) | Phase 1 | Completed | Sep 1, 2021 | Aug 14, 2023 (actual) |
| NCT04659122 | A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia | Phase 1 | Terminated | Aug 17, 2021 | Feb 23, 2023 (actual) |
NIH awards 1
- NIH award 1R44HL186892-01 FY2026: $1,906,253 awarded for that fiscal year; activity R44 (SBIR); PI SALZBERG, MARC; recipient as written: AIRWAY THERAPEUTICS, INC., Atlanta, GA. A Randomized,Phase 2b/3 Study to Evalua source ↗